Lupin announced that its US subsidiary, Lupin Pharmaceuticals has launched the all new InspiraChamber Anti-Static Valued Holding Chamber (VHC) under a strategic licensing agreement with the New Jersey based respiratory research and development company Inspirx.

The agreement grants Lupin exclusive rights to promote distribute and market InspiraChamber VHC in the United States.

"We are very excited with the addition of InspiraChamber VHC to our brand business portfolio. The launch demonstrates Lupin's commitment to grow its brand franchise n the US and bring meaningful product to patients in the country. The launch also heralds Lupin's entry into the larger US inhalation and related markets," said Vinita Gupta, chief executive officer, Lupin.
 
Shares of the company gained Rs 26.05, or 1.57%, to settle at Rs 1,685. The total volume of shares traded was 46,267 at the BSE (Wednesday).